DGIdb - VEGFA Gene Record

VEGFA 7422 Druggable GenomeClinically Actionable

Alternate Names:

7422
VASCULAR ENDOTHELIAL GROWTH FACTOR A
VEGFA
MVCD1
VEGF
VPF
192240
12680
ENSG00000112715
OTTHUMG00000014745
P15692
VEGF-A
Vascular permeability factor
VEGFA_HUMAN
PA37302
VASCULAR ENDOTHELIAL GROWTH FACTOR
T96721
T20761
6071

Gene Info:

Target Subclass	Growth factor
Target Class	Ligand
Target Subclass	Ligand
Target Main Class	Other
Gene Biotype	PROTEIN_CODING

(15 More Sources)

Gene Categories: Category Details

CELL SURFACE
GROWTH FACTOR
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Blann et al., 2001, Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate., Am. J. Cardiol.
Browning et al., 2012, Aflibercept for age-related macular degeneration: a game-changer or quiet addition?, Am. J. Ophthalmol.
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Gampenrieder SP et al., 2017, Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer., Pharmacogenomics J
Hein A et al., 2015, Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study., Int J Cancer
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Miyake M et al., 2014, Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia., Ophthalmology
Abedi F et al., 2013, Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration., Ophthalmology
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Gerber et al., 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies., Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Sathornsumetee S et al., 2008, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan., J Clin Oncol
Han K et al., 2016, Population pharmacokinetics of bevacizumab in cancer patients with external validation., Cancer Chemother Pharmacol
Scartozzi M et al., 2014, VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study., Int J Cancer
Lee JH et al., 2013, Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma., Cancer
He YJ et al., 2016, Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial., Pharmacogenomics J
Zaslau et al., 2006, Pentosan polysulfate (Elmiron): in vitro effects on prostate cancer cells regarding cell growth and vascular endothelial growth factor production., Am. J. Surg.
Eechoute K et al., 2012, Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension., Clin Pharmacol Ther
Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina
Lazzeri S et al., 2013, VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration., Pharmacogenomics
Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis
Smailhodzic D et al., 2012, Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration., Ophthalmology
Bakri et al., 2007, Pharmacokinetics of intravitreal ranibizumab (Lucentis)., Ophthalmology
Rosenfeld et al., 2006, Ranibizumab: Phase III clinical trial results., Ophthalmol Clin North Am
Gaudreault et al., Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits., Retina (Philadelphia, Pa.)
Gaudreault et al., 2005, Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration., Invest. Ophthalmol. Vis. Sci.
Ferrara et al., 2006, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration., Retina (Philadelphia, Pa.)
Pieramici et al., 2006, Ranibizumab: treatment in patients with neovascular age-related macular degeneration., Expert Opin Biol Ther
Michels et al., 2005, [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]., Klin Monbl Augenheilkd
Spitzer et al., 2008, Treatment of age-related macular degeneration: focus on ranibizumab., Clin Ophthalmol
Kourlas et al., 2007, Ranibizumab for the treatment of neovascular age-related macular degeneration: a review., Clin Ther
Nguyen et al., 2006, Vascular endothelial growth factor is a critical stimulus for diabetic macular edema., Am. J. Ophthalmol.
Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
Derosa L et al., 2014, Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients., Cancer
Koutras AK et al., 2014, Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel., Pharmacogenomics J
Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg
Lacchini R et al., 2013, VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction., Pharmacogenomics J
Goto et al., 2004, Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats., Virchows Arch.
Dejneka NS et al., 2008, Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes., Mol Vis
Molostvov et al., 2004, The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures., Br. J. Haematol.
Lee et al., 2001, Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication., Clin. Sci.
Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
Oliveira-Paula GH et al., 2015, Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril., Eur J Clin Pharmacol

RANIBIZUMAB VEGFA

Interaction Score: 8.54

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

Trial Name Lucentis

PMIDs:
23953100 23842101 23570466 23559864 23149126 22840423 18054637 16935211 18046235 15671306 17031284 17049020 15973626 19668384 18035187 17046701

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
BEVASIRANIB VEGFA

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name bevasiranib, Cand5

Novel drug target Established target

PMIDs:
18523657

Sources:
TdgClinicalTrial
PEGAPTANIB SODIUM VEGFA

Interaction Score: 3.25

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Macugen

Novel drug target Established target

Mechanism of Interaction Vascular endothelial growth factor A antagonist

PMIDs:
23953100

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB
ELMIRON VEGFA

Interaction Score: 3.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17071199

Sources:
NCI
AFLIBERCEPT VEGFA

Interaction Score: 2.28

Interaction Types & Directionality:

antibody (inhibitory)

binder

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

Trial Name AVE-0005

PMIDs:
22813448 20124951

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB TTD
RISUTEGANIB VEGFA

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
BROLUCIZUMAB VEGFA

Interaction Score: 1.63

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BEVACIZUMAB 111IN VEGFA

Interaction Score: 1.63

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A binding agent

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BEVACIZUMAB VEGFA

Interaction Score: 1.05

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Avastin

Novel drug target Established target

Notes

PMIDs:
27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD
MP-0250 VEGFA

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CDC-801 VEGFA

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14717786

Sources:
NCI
NAVICIXIZUMAB VEGFA

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ZALTRAP VEGFA

Interaction Score: 0.81

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes Fusion protein of extracellular domain portions from VEGFR-1 and VEGFR-2 combined with FC of human IGG

PMIDs:
None found

Sources:
TALC
ABICIPAR PEGOL VEGFA

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
SILDENAFIL VEGFA

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007311

Sources:
PharmGKB
CONBERCEPT VEGFA

Interaction Score: 0.41

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SQUALAMINE VEGFA

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CILOSTAZOL VEGFA

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11524048

Sources:
NCI
DOMATINOSTAT VEGFA

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name 4SC-203

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
OXALIPLATIN VEGFA

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB
LEUCOVORIN VEGFA

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
ENALAPRIL VEGFA

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26002049

Sources:
PharmGKB
MUPARFOSTAT VEGFA

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
GENTAMICIN VEGFA

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14986132

Sources:
NCI
CAPECITABINE VEGFA

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
LENALIDOMIDE VEGFA

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
FENOFIBRATE VEGFA

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11356390

Sources:
NCI
IRINOTECAN VEGFA

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
PHENYTOIN VEGFA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15458527

Sources:
NCI
DOCETAXEL VEGFA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26100253 25111199 24061601

Sources:
PharmGKB
SUNITINIB VEGFA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22948895

Sources:
PharmGKB
FLUOROURACIL VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB
SORAFENIB VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24510746 22736425

Sources:
PharmGKB
REGORAFENIB VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CELECOXIB VEGFA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22336956

Sources:
PharmGKB
CARBOPLATIN VEGFA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26194361

Sources:
PharmGKB
OSI-632 VEGFA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CISPLATIN VEGFA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24090479

Sources:
PharmGKB

Ensembl: ENSG00000112715
- Version: 101_38
Alternate Names:

VEGFA Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P15692
- Version: January-2014
Alternate Names:

VEGFA Gene Symbol

Gene Info:

Target Class Ligand

Target Subclass Ligand

Target Subclass Growth factor

Publications:
TEND: P15692
- Version: 01-August-2011
Alternate Names:

P15692 Uniprot Accession

VEGFA_HUMAN Uniprot Id

VEGF Gene Symbol

Gene Info:

Target Subclass Ligand

Target Subclass Growth factor

Target Main Class Other

Publications:

PharmGKB: VEGFA

Version: 18-August-2020

Alternate Names:

PA37302 PharmGKB ID

Gene Info:

Publications:

Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J

Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One

Lazzeri S et al., 2013, VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration., Pharmacogenomics

CIViC: VEGFA

Version: 14-September-2020

Alternate Names:

7422 Entrez Gene ID

6071 CIViC Gene ID

Gene Info:

Publications:

Sathornsumetee S et al., 2008, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan., J Clin Oncol

TTD: Vascular endothelial growth factor A
- Version: 2020.06.01
Alternate Names:

VEGFA TTD Gene Abbreviation

T20761 TTD Target ID

Gene Info:

Publications:

Fan G et al., 2015, Bispecific antibodies and their applications., J Hematol Oncol

NCI: VEGFA

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg

Lee et al., 2001, Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication., Clin. Sci.

Mills et al., 2004, The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer., Clin. Cancer Res.

MyCancerGenome: VEGFA
- Version: 20-Jun-2017
Alternate Names:

7422 Entrez Gene Id

VEGFA MyCancerGenome Gene Symbol

VEGFA MyCancerGenome Reported Gene Name

Gene Info:

Publications:
TALC: VEGF-A
- Version: 12-May-2016
Alternate Names:

VEGF-A Gene Symbol

Gene Info:

Publications:
HingoraniCasas: ENSG00000112715
- Version: 31-May-2017
Alternate Names:

ENSG00000112715 Gene Symbol

VEGFA Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: VEGF
- Version: chembl_23
Alternate Names:

VEGF-A UNIPROT

VEGF GENE_SYMBOL

VEGFA GENE_SYMBOL

Gene Info:

Publications:
TALC: VEGF
- Version: 12-May-2016
Alternate Names:

VEGF Gene Symbol

Gene Info:

Publications:
GO: VEGFA
- Version: 01-February-2022
Alternate Names:

VEGF GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, GROWTH FACTOR

Publications:
Tempus: VEGFA
- Version: 11-November-2018
Alternate Names:

VEGFA Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Vascular endothelial growth factor
- Version: 2020.06.01
Alternate Names:

VEGF TTD Gene Abbreviation

T96721 TTD Target ID

Gene Info:

Publications:
ClearityFoundationClinicalTrial: VEGFA
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MyCancerGenomeClinicalTrial: VEGFA
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: VEGFA
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: VEGFA
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Mechanism of Interaction	Vascular endothelial growth factor A inhibitor
Direct Interaction	yes
Trial Name	Lucentis

Trial Name	bevasiranib, Cand5
Novel drug target	Established target

Trial Name	Macugen
Novel drug target	Established target
Mechanism of Interaction	Vascular endothelial growth factor A antagonist

Mechanism of Interaction	Vascular endothelial growth factor A binding agent
Direct Interaction	yes

7422	Entrez Gene Id
VEGFA	MyCancerGenome Gene Symbol
VEGFA	MyCancerGenome Reported Gene Name

antibody (inhibitory)
binder
inhibitor (inhibitory)

antibody (inhibitory)
inhibitor (inhibitory)

VEGFA Gene Record

VEGFA 7422 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor A inhibitor Direct Interaction yes Trial Name Lucentis

PMIDs: 23953100 23842101 23570466 23559864 23149126 22840423 18054637 16935211 18046235 15671306 17031284 17049020 15973626 19668384 18035187 17046701

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name bevasiranib, Cand5 Novel drug target Established target

PMIDs: 18523657

Sources: TdgClinicalTrial

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name Macugen Novel drug target Established target Mechanism of Interaction Vascular endothelial growth factor A antagonist

PMIDs: 23953100

Sources: TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17071199

Sources: NCI

Interaction Types & Directionality: antibody (inhibitory) binder inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor A inhibitor Direct Interaction yes Trial Name AVE-0005

PMIDs: 22813448 20124951

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor A inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor A binding agent Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Avastin Novel drug target Established target Notes

PMIDs: 27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14717786

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Notes Fusion protein of extracellular domain portions from VEGFR-1 and VEGFR-2 combined with FC of human IGG

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007311

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor A inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11524048

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Trial Name 4SC-203 Novel drug target Established target

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

Trial Name Lucentis

PMIDs:
23953100 23842101 23570466 23559864 23149126 22840423 18054637 16935211 18046235 15671306 17031284 17049020 15973626 19668384 18035187 17046701

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name bevasiranib, Cand5

Novel drug target Established target

PMIDs:
18523657

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Macugen

Novel drug target Established target

Mechanism of Interaction Vascular endothelial growth factor A antagonist

PMIDs:
23953100

Sources:
TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17071199

Sources:
NCI

Interaction Types & Directionality:

antibody (inhibitory)

binder

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

Trial Name AVE-0005

PMIDs:
22813448 20124951

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A binding agent

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Avastin

Novel drug target Established target

Notes

PMIDs:
27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
14717786

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes Fusion protein of extracellular domain portions from VEGFR-1 and VEGFR-2 combined with FC of human IGG

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
23007311

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
11524048

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name 4SC-203

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25955730 20125120

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26002049

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Vascular endothelial growth factor A inhibitor

PMIDs:
None found

Sources:
ChemblInteractions